Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Alefacept is a recombinant human fusion protein that binds to CD2 on memory T cells, preventing their activation and reducing their number. It is used in the treatment of moderate to severe chronic plaque psoriasis. Intramuscular administration one dose per week for 12 weeks.
At the time of the last update, we found no published data on its excretion in breast milk.
Its high molecular weight makes it unlikely to pass into breast milk.
Its low oral bioavailability makes it difficult to pass into infant plasma from ingested breast milk since, due to its protein nature, it is degraded in the gastrointestinal tract and is not absorbed.